PharmaEssentia Corporation

TWSE:6446 Stock Report

Market Cap: NT$102.6b

PharmaEssentia Management

Management criteria checks 2/4

PharmaEssentia's CEO is Ko-Chung Lin, appointed in Jan 2017, has a tenure of 7.33 years. directly owns 1.62% of the company’s shares, worth NT$1.66B. The average tenure of the management team and the board of directors is 4.6 years and 4.5 years respectively.

Key information

Ko-Chung Lin

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure7.3yrs
CEO ownership1.6%
Management average tenure4.6yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?

Apr 02
Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?

Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term

Mar 18
Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term

PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 06
PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates

Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade

Mar 04
Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade

PharmaEssentia (GTSM:6446) Is Using Debt Safely

Feb 10
PharmaEssentia (GTSM:6446) Is Using Debt Safely

What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 06
What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

PharmaEssentia Corporation's (GTSM:6446) Profit Outlook

Nov 30
PharmaEssentia Corporation's (GTSM:6446) Profit Outlook

CEO Compensation Analysis

How has Ko-Chung Lin's remuneration changed compared to PharmaEssentia's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-NT$624m

Sep 30 2023n/an/a

-NT$890m

Jun 30 2023n/an/a

-NT$1b

Mar 31 2023n/an/a

-NT$2b

Dec 31 2022n/an/a

-NT$1b

Sep 30 2022n/an/a

-NT$2b

Jun 30 2022n/an/a

-NT$2b

Mar 31 2022n/an/a

-NT$3b

Dec 31 2021NT$9mNT$9m

-NT$3b

Sep 30 2021n/an/a

-NT$3b

Jun 30 2021n/an/a

-NT$3b

Mar 31 2021n/an/a

-NT$2b

Dec 31 2020NT$9mNT$9m

-NT$2b

Sep 30 2020n/an/a

-NT$1b

Jun 30 2020n/an/a

-NT$862m

Mar 31 2020n/an/a

-NT$856m

Dec 31 2019NT$9mNT$8m

-NT$843m

Compensation vs Market: Insufficient data to establish whether Ko-Chung's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Ko-Chung's compensation has increased whilst the company is unprofitable.

CEO

Ko-Chung Lin

7.3yrs

Tenure

NT$9,389,000

Compensation

Mr. Ko-Chung Lin, Ph D., is the Founder and Chief Strategy Officer of PharmaEssentia Corporation and has been its Chief Executive Officer since January 01, 2017. He also serves as a Director at PharmaEssen...

Leadership Team

NamePositionTenureCompensationOwnership
Ching-Leou Teng
Chairman & Chief Pharmaceutical Officer11.7yrsNT$8.49m1.02%
NT$ 1.0b
Ko-Chung Lin
Founder7.3yrsNT$9.39m1.62%
NT$ 1.7b
Chan-Kou Hwang
Presidentno dataNT$8.49m0.61%
NT$ 621.4m
Snow Chang
Accounting Manager & Senior Manager of Finance8.6yrsno datano data
Samuel Lin
VP and Head of Business Operations & Strategy2.3yrsno datano data
Lih-Ling Lin
Chief Scientific Officer1.8yrsno data0.020%
NT$ 20.1m
Rachel Lipsitz
VP and Head of Corporate Communications & Advocacy2.3yrsno datano data
Roddy Mcilwain
Senior VP and Head of Sales & Marketing3.3yrsno datano data
Anjana Pursnani
Senior VP & Head of People2.3yrsno datano data
Albert Qin
Chief Medical Officer7.3yrsno data0.022%
NT$ 22.6m
Narihisa Miyachi
Head of Japan Medical Affairs5.8yrsno datano data
Yen-Tung Luan
Chief Operating Officer of Taichung Plant5.8yrsno datano data

4.6yrs

Average Tenure

Experienced Management: 6446's management team is considered experienced (4.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ching-Leou Teng
Chairman & Chief Pharmaceutical Officer11.7yrsNT$8.49m1.02%
NT$ 1.0b
Ko-Chung Lin
Founder2.8yrsNT$9.39m1.62%
NT$ 1.7b
Chan-Kou Hwang
President9yrsNT$8.49m0.61%
NT$ 621.4m
Patrick Yang
Independent Director10.2yrsNT$75.00kno data
Jinn-Der Chang
Independent Director10.2yrsNT$120.00k0.029%
NT$ 29.5m
Ben-Yuan Chen
Director17.9yrsNT$120.00k0.72%
NT$ 741.7m
Jien-Heh Tien
Independent Director5.9yrsNT$120.00k0.00060%
NT$ 615.4k
Norio Komatsu
Chairperson of Japan3yrsno datano data
Yen Ching Hwang
Director2.8yrsNT$95.00kno data
Shen Yi Li
Director2.8yrsNT$95.00k0.25%
NT$ 254.4m
Shen You Gong
Director2.8yrsNT$95.00k0.0032%
NT$ 3.2m
Chien-Hsin Lai
Director1.3yrsno datano data

4.5yrs

Average Tenure

Experienced Board: 6446's board of directors are considered experienced (4.5 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.